, Tracking Stock Market Picks
Enter Symbol:
Curis, Inc. (CRIS) [hlAlert]

down 30.55 %

Curis, Inc. (CRIS) rated Outperform with price target $6 by Oppenheimer

Posted on: Friday,  Dec 9, 2011  9:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Curis, Inc. (NASDAQ: CRIS) on 12/09/2011, when the stock price was $3.60. Since
then, Curis, Inc. has lost 30.56% as of 01/22/2016's recent price of $2.50.
If you would have followed this Oppenheimer's recommendation on CRIS, you would have lost 30.55% of your investment in 1505 days.

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/9/2011 9:25 AM Buy
3.60 6.00
as of 12/30/2011
1 Week up  4.00 %
1 Month up  30.00 %
3 Months   
1 YTD up  30.00 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy